Alpine Immune Sciences Announces Upcoming Scientific Presentations at SITC and ACR/ARHP 2019 Annual Meetings
October 02 2019 - 7:30AM
Business Wire
Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading
clinical-stage immunotherapy company focused on developing
innovative treatments for cancer, autoimmune/inflammatory, and
other diseases, today announced planned poster presentations at
upcoming scientific meetings highlighting new preclinical data on
the Company’s lead programs: ALPN-101, a first-in-class dual
CD28/ICOS inhibitor for the treatment of autoimmune diseases, and
ALPN-202, a conditional CD28 costimulator and dual checkpoint
inhibitor for the treatment of cancers.
2019 Society for Immunotherapy of Cancer (SITC) Annual
Meeting – National Harbor, MD
Abstract Title: ALPN-202, a
Conditional CD28 Costimulator and Dual Checkpoint Inhibitor,
Utilizes Multiple Mechanisms to Elicit Potent Anti-Tumor Immunity
Superior to Checkpoint Blockade Alone Poster #: P793
Date: Friday, November 8, 2019 Time: 7:00 a.m. – 8:00
p.m. ET
Abstract Title: ALPN-202, a
Conditional CD28 Costimulator and Dual Checkpoint Inhibitor,
Enhances the Activity of Multiple Standard of Care Modalities
Poster #: P467 Date: Friday, November 8, 2019
Time: 7:00 a.m. – 8:00 p.m. ET
American College of Rheumatology 2019 ACR/ARHP Annual Meeting
– Atlanta, GA
Abstract Title: ALPN-101, a
First-in-Class Dual ICOS/CD28 Antagonist, Suppresses Key Effector
Mechanisms Underlying Rheumatoid and Psoriatic Arthritis Session
Title: Spondyloarthritis Including PsA–Clinical Poster II:
Treatment of Axial Spondyloarthritis and Psoriatic Arthritis
Date: Monday, November 11, 2019 Time: 9:00 a.m. –
11:00 a.m. ET
Abstract Title: ALPN-101, a
First-in-Class Dual ICOS/CD28 Antagonist, Suppresses Key Effector
Mechanisms Associated with Sj�gren’s Syndrome Session Title:
Sj�grenʼs Syndrome–Basic & Clinical Science Poster I
Date: Tuesday, November 12, 2019 Time: 9:00 a.m. –
11:00 a.m. ET
About Alpine Immune Sciences, Inc.
Alpine Immune Sciences, Inc. is committed to leading a new wave
of immune therapeutics, creating potentially powerful
multifunctional immunotherapies to improve patients’ lives via
unique protein engineering technologies. Alpine has two lead
programs. The first, ALPN-101 for autoimmune/inflammatory diseases,
is a selective dual T-cell costimulation blocker engineered to
reduce pathogenic T and B cell immune responses by blocking ICOS
and CD28.. The second, ALPN-202 for cancer, is a conditional CD28
costimulator and dual checkpoint inhibitor. Alpine is backed by
world-class research and development capabilities, a
highly-productive scientific platform, and a proven management
team. For more information, visit www.alpineimmunesciences.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191002005198/en/
Investor Relations: Pure Communications Courtney Dugan,
212-257-6723 cdugan@purecommunications.com
Media Relations: Pure Communications Sheryl Seapy, 213-262-9390
sseapy@w2ogroup.com
Alpine Immune Sciences (NASDAQ:ALPN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alpine Immune Sciences (NASDAQ:ALPN)
Historical Stock Chart
From Apr 2023 to Apr 2024